Search

Displaying results 1771 - 1780 of 7604 in total
  1. Drug

    Silodosin

    go.drugbank.com/drugs/DB06207
    ApprovedInvestigational

    [A231159] Silodosin works by binding to α<sub>1A</sub>-adrenoceptors with high affinity and relaxing the lower urinary tract, thereby improving urinary symptoms and alleviating bladder outlet obstruction … [A231159] Silodosin was first approved by the FDA in October 2008 [A231159] and it is also approved in Europe and Canada.

  2. Drug

    Plecanatide

    go.drugbank.com/drugs/DB13170
    ApprovedInvestigational

    Plecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC). … It should not be used in children less than six years of age, and should be avoided in patients six years to 18 years of age

  3. Drug

    Efgartigimod alfa

    go.drugbank.com/drugs/DB15270
    ApprovedInvestigational

    Myasthenia gravis (MG) is an autoimmune disorder characterized by significant muscle weakness - particularly in the eye, throat, and extremities - caused by autoantibodies attacking the neuromuscular junction … Efgartigimod alfa for intravenous use was granted FDA approval on December 17, 2021[L39501] and European Commission approval on August 11, 2022 for use in patients with myasthenia gravis.

  4. Drug

    Tepotinib

    go.drugbank.com/drugs/DB15133
    ApprovedInvestigational

    Tepotinib was first approved in Japan in March 2020 for the treatment of non-small cell lung cancers (NSCLC) with _MET_ alterations, and was subsequently granted accelerated approval by the US FDA in February … Tepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors.

  5. Drug

    Retifanlimab

    go.drugbank.com/drugs/DB15766
    ApprovedInvestigational

    By blocking the PD-1/PD-L1/2 pathway, retifanlimab potentiates T-cell activity and boosts the immune response against cancer cells. … [L45608,L45618] On March 2023, the FDA granted accelerated approval to retifanlimab for a different indication, the treatment of metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).

  6. Drug

    Nadolol

    go.drugbank.com/drugs/DB01203
    ApprovedInvestigational

    [L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and … [A34177] Nadolol was granted FDA approval on 10 December 1979.[L7922]

    Categories: Beta Blocking Agents, Non-Selective, Beta Blocking Agents, Non-Selective, and ThiazidesProducts: NADOLOL MK 80 MG TABLETAS
  7. Drug

    Dapiprazole

    go.drugbank.com/drugs/DB00298
    Approved

    It is found in ophthalmic solutions used to reverse mydriasis after an eye examination.

    Synonyms: 5,6,7,8-Tetrahydro-3-(2-(4-(o-tolyl)-1-piperazinyl)ethyl)-s-triazolo(4,3-a)pyridine
  8. Drug

    Suprofen

    go.drugbank.com/drugs/DB00870
    ApprovedWithdrawn

    It is no longer approved for use in the United States.

    Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-Narcotic
  9. Drug

    Fursultiamine

    go.drugbank.com/drugs/DB08966
    Approved

    It has also been suggested for several non-deficiency disorders but has not yet proven useful. Fursultiamine is a vitamin B1 derivative.

  10. Drug

    Tebentafusp

    go.drugbank.com/drugs/DB15283
    ApprovedInvestigational

    to be approved by the FDA. … This approval marks the first bispecific T cell engager to be approved by the FDA to treat a solid tumour and being the first and only therapy for the treatment of unresectable or metastatic uveal melanoma